A vaccine and diagnostic target for Clostridium bolteae, an autism-associated bacterium

Vaccine

Volumn 31, Issue 26, 2013, Pages 2787-2790

  Pequegnat, Brittany ^a   Sagermann, Martin ^b   Valliani, Moez ^a   Toh, Michael ^a   Chow, Herbert ^b   Allen Vercoe, Emma ^a   Monteiro, Mario A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Stellar Biotechnologies Inc   (United States)

Author keywords

Clostridium bolteae; Diagnostic; Diarrhea; Polysaccharide; Regressive autism; Vaccine

Indexed keywords

BACTERIAL POLYSACCHARIDE; CLOSTRIDIUM BOLTEAE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; CLOSTRIDIUM; CLOSTRIDIUM BOLTEAE; DRUG CONFORMATION; DRUG TARGETING; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; AUTISTIC DISORDER; BACTERIAL VACCINES; CELL WALL; CLOSTRIDIUM; CLOSTRIDIUM INFECTIONS; DISACCHARIDES; MONOSACCHARIDES; POLYSACCHARIDES, BACTERIAL; RABBITS; VACCINES, SYNTHETIC;

EID: 84878418309     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.018     Document Type: Article

References (33)

1. Finegold S.M., Dowd S.E., Gontcharova V., Liu C., Henley K.E., Wolcott R.D., et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 2010, 16:444-453.
2. Parracho H.M., Bingman M.O., Gibson G.R., McCartney A.L. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 2005, 54:987-991.
3. MacFabe D.F., Cain D.P., Rodriguez-Capote K., Franklin A.E., Hoffman J.E., Boon F., et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res 2007, 176:149-169.
4. Cuche G., Malbert C.H. Short-chain fatty acids present in the ileum inhibit fasting gastrointestinal motility in conscious pigs. Neurogastroent Motil 1999, 11:219-225.
5. Finegold S.M., Molitoris D., Song Y., Liu C., Vaisanen M.-L., Bolte E., et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002, 35:S6-S16.
6. Song Y., Liu C., Molitoris D.R., Tomzynski T.J., Lawson P.A., Collins M.D., et al. Clostridium bolteae sp. nov., isolated from human sources. Syst Appl Microbiol 2003, 26:84-89.
7. Venugopal A.A., Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012, 55:S71-S76.
8. Finegold S.M., Downes J., Summanen P.H. Microbiology of regressive autism. Anaerobe 2012, 18:260-262.
9. Sandler R.H., Finegold S.M., Bolte E.R., Buchanan C.P., Maxwell A.P., Vaisanen M.L., et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000, 15:429-435.
10. Guerry P., Poly F., Riddle M., Maue A.C., Chen Y.-H., Monteiro M.A. Campylobacter polysaccharide capsules: virulence and vaccines. Frontiers Cell Infect Microbiol 2012, 10.3389/fcimb.2012.00007.
11. Adamo R., Romano M.R., Berti F., Leuzzi R., Tontini M., Danieli E., et al. Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide. ACS Chem Biol 2012, 7:1420-1428.
12. Monteiro M.A., Ma Z., Bertolo L., Jiao Y., Arroyo L., Hodgins D., et al. Carbohydrate-based Clostridium difficile vaccines. Exp Rev Vaccines 2013, 12:421-431.
13. Westphal O.K., Jann K. Bacterial lipooligosaccharide. Extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 1965, 5:83-91.
14. Bertolo L., Boncheff A.G., Ma Z., Chen Y.-H., Wakeford T., Friendship R.M., et al. Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile-ETEC conjugate vaccine. Carbohydr Res 2012, 354:79-86.
15. Sawardeker J.S., Sloneker J.H., Jeanes A. Quantitative determination of monosaccharides as their alditol acetates by gas liquid chromatography. Anal Chem 1965, 37:1602-1604.
16. Ciucanu I., Kerek F. A simple and rapid method for the permethylation of carbohydrates. Carbohydr Res 1984, 131:209-217.
17. Case D.A., Darden T.A., Cheatham T.E., Simmerling C.L., Wang J., Duke R.E., et al. Amber 10 2008, University of California, San Francisco.
18. Kirschner K.N., Yongye A.B., Tschampel S.M., Daniels C.R., Foley B.L., Woods R.J. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem 2008, 29:622-655.
19. Ganeshapillai J., Vinogradov E., Rousseau J., Weese J.S., Monteiro M.A. Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr Res 2008, 343:703-710.
20. Kalelkar S., Glushka J., van Halbeek H., Morris L.C., Cherniak R. Structure of the capsular polysaccharide of Clostridium perfringens Hobbs 5 as determined by NMR spectroscopy. Carbohydr Res 1997, 299:119-128.
21. Sheng S., Cherniak R. Structure of the capsular polysaccharide of Clostridium perfringens Hobbs 10 determined by NMR spectroscopy. Carbohydr Res 1997, 305:65-72.
22. Watt G., Leoff C., Harper A.D., Bar-Peled M. A bifunctional 3,5-epimerase/4-keto reductase for nucleotide-rhamnose synthesis in Arabidopsis. Plant Physiol 2004, 134:1337-1346.
23. Rocchetta H.L., Burrows L.L., Lam J.S. Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev 1999, 63:523-553.
24. Ramm M., Wolfender J.-L., Queiroz E.F., Hostettmann K., Hamburger M. Rapid analysis of nucleotide-activated sugars by high-performance liquid chromatography coupled with diode-array detection, electrospray ionization mass spectrometry and nuclear magnetic resonance. J Chromatogr A 2004, 1034:139-148.
25. D'Eufemia P., Celli M., Finocchiaro R., Pacifico L., Viozzi L., Zaccagnini M., et al. Abnormal intestinal permeability in children with autism. Acta Paediatr 1996, 85:1076-1079.
26. Williams B.L., Hornig M., Buie T., Bauman M.L., Cho Paik M., Wick I., et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One 2011, 6(9):e24585.
27. Merrigan M.M., Sambol S.P., Johnson S., Gerding D.N. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009, (Suppl. 1):S46-S50. 10.1016/S0924-8579(09)70017-2.
28. Calabi E., Ward S., Wren B., Paxton T., Panico M., Morris H., et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 2001, 40:1187-1199.
29. Waligora A.J., Hennequin C., Mullany P., Bourlioux P., Collignon A., Karjalainen T. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 2001, 69:2144-2153.
30. Sebaihia M., Wren B.W., Mullany P., Fairweather N.F., Minton N., Stabler R., et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006, 38:779-786.
31. Cappelletti A., Romano M.R., Cakici O.S., Adamo R., Berti F., Proietti D., et al. Conjugate vaccine against Clostridium difficile. Glycoconj J 2011, 28:265.
32. Danieli E., Lay L., Proietti D., Berti F., Costantino P., Adamo R. First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. Org Lett 2011, 13:378-381.
33. Oberli M.A., Hecht M.L., Bindschädler P., Adibekian A., Adam T., Seeberger P.H. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 2011, 18:580-588.